{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sicinska E"],"funding":["Sarcoma Foundation of America","National Cancer Institute","NCI NIH HHS","Cure Alveolar Soft Part Sarcoma International","Sarcoma Foundation of America (SFA)"],"pagination":["2247-2264"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11250573"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["84(14)"],"pubmed_abstract":["Alveolar soft part sarcoma (ASPS) is a rare mesenchymal malignancy driven by the ASPSCR1::TFE3 fusion. A better understanding of the mechanisms by which this oncogenic transcriptional regulator drives cancer growth is needed to help identify potential therapeutic targets. In this study, we characterized the transcriptional and chromatin landscapes of ASPS tumors and preclinical models, identifying the essential role of ASPSCR1::TFE3 in tumor cell viability by regulating core transcriptional programs involved in cell proliferation, angiogenesis, and mitochondrial biology. ASPSCR1::TFE3 directly interacted with key epigenetic regulators at enhancers and promoters to support ASPS-associated transcription. Among the effector programs driven by ASPSCR1::TFE3, cell proliferation was driven by hi"],"journal":["Cancer research"],"pubmed_title":["ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs."],"pmcid":["PMC11250573"],"funding_grant_id":["K08 CA245235"],"pubmed_authors":["Kerfoot JA","Sicinska E","Kola VSR","Hsieh YH","Hemming ML","Church AJ","Taddei ML","Landesman Y","Landesman-Bollag E","Al-Ibraheemi A"],"additional_accession":[]},"is_claimable":false,"name":"ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs.","description":"Alveolar soft part sarcoma (ASPS) is a rare mesenchymal malignancy driven by the ASPSCR1::TFE3 fusion. A better understanding of the mechanisms by which this oncogenic transcriptional regulator drives cancer growth is needed to help identify potential therapeutic targets. In this study, we characterized the transcriptional and chromatin landscapes of ASPS tumors and preclinical models, identifying the essential role of ASPSCR1::TFE3 in tumor cell viability by regulating core transcriptional programs involved in cell proliferation, angiogenesis, and mitochondrial biology. ASPSCR1::TFE3 directly interacted with key epigenetic regulators at enhancers and promoters to support ASPS-associated transcription. Among the effector programs driven by ASPSCR1::TFE3, cell proliferation was driven by hi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-01T14:36:18.61Z","creation":"2025-04-06T01:19:05.354Z"},"accession":"S-EPMC11250573","cross_references":{"pubmed":["38657118"],"doi":["10.1158/0008-5472.can-23-2115","10.1158/0008-5472.CAN-23-2115"]}}